What is Leerink Partnrs’ Estimate for STOK FY2024 Earnings?

Stoke Therapeutics, Inc. (NASDAQ:STOK) – Research analysts at Leerink Partnrs increased their FY2024 EPS estimates for Stoke Therapeutics in a report issued on Tuesday, November 5th. Leerink Partnrs analyst M. Goodman now anticipates that the company will earn ($2.00) per share for the year, up from their prior estimate of ($2.05). Leerink Partnrs currently has a “Strong-Buy” rating on the stock. The consensus estimate for Stoke Therapeutics’ current full-year earnings is ($2.10) per share. Leerink Partnrs also issued estimates for Stoke Therapeutics’ Q4 2024 earnings at ($0.50) EPS, FY2025 earnings at ($2.25) EPS, FY2026 earnings at ($2.60) EPS, FY2027 earnings at ($2.75) EPS and FY2028 earnings at ($2.60) EPS.

Stoke Therapeutics (NASDAQ:STOK) last released its earnings results on Tuesday, November 5th. The company reported ($0.47) EPS for the quarter, topping the consensus estimate of ($0.52) by $0.05. Stoke Therapeutics had a negative return on equity of 54.45% and a negative net margin of 629.90%. The business had revenue of $4.89 million during the quarter, compared to analysts’ expectations of $3.46 million.

Several other brokerages have also commented on STOK. Needham & Company LLC reaffirmed a “buy” rating and issued a $22.00 price objective on shares of Stoke Therapeutics in a research report on Wednesday. Leerink Partners assumed coverage on Stoke Therapeutics in a research report on Monday, October 14th. They issued an “outperform” rating and a $18.00 price objective on the stock. Finally, HC Wainwright reissued a “buy” rating and set a $35.00 price objective on shares of Stoke Therapeutics in a research note on Wednesday. One research analyst has rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Stoke Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $20.83.

Stoke Therapeutics Stock Up 4.6 %

Shares of Stoke Therapeutics stock opened at $13.88 on Friday. The business has a 50 day moving average price of $13.21 and a 200-day moving average price of $13.72. Stoke Therapeutics has a 52 week low of $3.77 and a 52 week high of $17.58. The company has a market cap of $735.22 million, a PE ratio of -6.61 and a beta of 0.95.

Insiders Place Their Bets

In other Stoke Therapeutics news, major shareholder Skorpios Trust sold 1,937,500 shares of the company’s stock in a transaction that occurred on Thursday, September 19th. The stock was sold at an average price of $14.05, for a total value of $27,221,875.00. Following the completion of the sale, the insider now owns 8,906,181 shares of the company’s stock, valued at $125,131,843.05. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 11.30% of the company’s stock.

Institutional Investors Weigh In On Stoke Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Quest Partners LLC bought a new position in Stoke Therapeutics during the 2nd quarter valued at approximately $29,000. Nisa Investment Advisors LLC raised its holdings in shares of Stoke Therapeutics by 53.2% during the second quarter. Nisa Investment Advisors LLC now owns 2,989 shares of the company’s stock valued at $40,000 after acquiring an additional 1,038 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in Stoke Therapeutics in the second quarter worth $123,000. State Board of Administration of Florida Retirement System bought a new stake in Stoke Therapeutics in the first quarter valued at $141,000. Finally, The Manufacturers Life Insurance Company increased its position in Stoke Therapeutics by 16.7% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 13,964 shares of the company’s stock valued at $189,000 after purchasing an additional 1,994 shares during the period.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.